Vaccine stocks and EV maker Lucid Technologies (LCID) are among today's biggest winners today. Vaccine makers, including Moderna (MRNA), Novavax (NVAX), and BioNTech (BNTX), are rallying after the first U.S. death from bird flu was announced yesterday. A closeup of a vial of the biotechnology company's vaccines. Meanwhile, Lucid's shares are climbing for a second straight day after the EV company reported higher-than-expected fourth-quarter deliveries yesterday. First Bird Flu Death The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu. According to the agency, the individual contracted the disease from animals, while it knew of no other cases in the state. The shares of Moderna, which is developing an mRNA-based vaccine for bird flu, are climbing 10%. In July, the company was given $176 million by the U.S. Department of Health and Human Services to create "a prepandemic vaccine against H5 avian influenza." Meanwhile,  Novavax and BioNTech are rising 13% and 4.5%, respectively this morning. GSK (GSK) and Sanofi (SNY) have both sold traditional vaccines against the disease to the U.S. Lucid Is Advancing Again Lucid's shares are rising nearly 4% today. Yesterday the company noted that it had delivered almost 3,100 EVs in the fourth quarter. That was much higher than analysts' average estimate of just 2,339 EVs. While we acknowledge the potential of MRNA, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey.